These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 30414038)

  • 1. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
    Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
    Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study.
    Forsythe SD; Erali RA; Sasikumar S; Laney P; Shelkey E; D'Agostino R; Miller LD; Shen P; Levine EA; Soker S; Votanopoulos KI
    Clin Cancer Res; 2021 Sep; 27(18):5141-5150. PubMed ID: 34210684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
    Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
    Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.
    Mazzocchi AR; Rajan SAP; Votanopoulos KI; Hall AR; Skardal A
    Sci Rep; 2018 Feb; 8(1):2886. PubMed ID: 29440675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform.
    Forsythe SD; Sasikumar S; Moaven O; Sivakumar H; Shen P; Levine EA; Soker S; Skardal A; Votanopoulos KI
    Ann Surg Oncol; 2020 Dec; 27(13):4950-4960. PubMed ID: 32632882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications.
    Forsythe SD; Sivakumar H; Erali RA; Wajih N; Li W; Shen P; Levine EA; Miller KE; Skardal A; Votanopoulos KI
    Ann Surg Oncol; 2022 Nov; 29(12):7354-7367. PubMed ID: 35780216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
    Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the Efficacy of HIPEC Through Bromelain: A Preclinical Investigation in Appendiceal Cancer.
    Wajih N; Erali RA; Forsythe SD; Schaaf CR; Shen P; Levine EA; Soker S; Morris DL; Votanopoulos KI
    Ann Surg Oncol; 2024 Aug; 31(8):5377-5389. PubMed ID: 38704503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
    Omohwo C; Nieroda CA; Studeman KD; Thieme H; Kostuik P; Ross AS; Holter DR; Gushchin V; Merriman B; Sardi A
    J Am Coll Surg; 2009 Sep; 209(3):308-12. PubMed ID: 19717034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection.
    Enomoto LM; Choudry MH; Bartlett DL; Totin L; Mann GN; Skitzki JJ; Perry KC; Votanopoulos KI; Levine EA; Shen P
    Ann Surg Oncol; 2020 Jan; 27(1):107-114. PubMed ID: 31368017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The establishment of kidney cancer organoid line in drug testing.
    Tse RT; Wong CY; Ding X; Cheng CK; Chow C; Chan RC; Ng JH; Tang VW; Chiu PK; Teoh JY; Wong N; To KF; Ng CF
    Cancer Med; 2024 Jun; 13(12):e7432. PubMed ID: 38923304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy.
    Liu G; Xiao X; Xia Y; Huang W; Chen W; Xu J; Chen S; Wang H; Wei J; Li H; Shu M; Lu X; Zhang C; He Y
    Front Med (Lausanne); 2022; 9():829033. PubMed ID: 35721089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Organoid-Based Preclinical Model of Human Gastric Cancer.
    Steele NG; Chakrabarti J; Wang J; Biesiada J; Holokai L; Chang J; Nowacki LM; Hawkins J; Mahe M; Sundaram N; Shroyer N; Medvedovic M; Helmrath M; Ahmad S; Zavros Y
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):161-184. PubMed ID: 30522949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
    Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
    Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.